# Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

> **NCT02944110** · NA · UNKNOWN · sponsor: **University Hospital, Gentofte, Copenhagen** · enrollment: 20 (estimated)

## Conditions studied

- Diabetes After Total Pancreatectomy

## Interventions

- **DRUG:** Glucagon receptor antagonist LY2409021
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02944110
- **Lead sponsor:** University Hospital, Gentofte, Copenhagen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2019-11
- **Final completion:** 2021-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944110, "Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02944110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*